Clinical trials: Cancer Prostate
Prostate Cancer, Solid Tumor, Adult
CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours
The hepatic enzyme, cytochrome P450 3A4 (CYP3A4) is important for the metabolism of many drugs including taxanes. Previous reported studies reported a decreases in docetaxel exposure in prostate cancer patients compared to…
- Trial name
- NCT05518799
- Testing
- Midazolam
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Image Guided Radiation Therapy For Prostate Cancer
During the 7 to 8 weeks of conformal radiotherapy for prostate carcinoma, the prostate has an intra-pelvic motion which is not detectable by the conventional portal imaging.
- Trial name
- NCT00433706
- Testing
- Control position by 3DOBI before the fraction, Standard imaging
- Where
- France
- Volunteers
- 470 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with…
- Trial name
- NCT00004014
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Surgery in Treating Patients With Prostate Cancer
RATIONALE: Prostatectomy may be an effective treatment for prostate cancer that has not responded to radiation therapy. PURPOSE: This phase II trial is studying how well prostatectomy works in treating patients with recurrent or…
- Trial name
- NCT00002938
- Testing
- conventional surgery
- Where
- 61 sites in United States
- Volunteers
- 49 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hormone Refractory Prostate Cancer
Radiotherapy vs Observation for CRPC
The purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with Castration resistant prostate cancer.
- Trial name
- NCT01590498
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Zhengzhou University
Prostate Cancer (Post Prostatectomy), Urinary Continence
Analysis of Immediate Urinary Continence Predictors After RS-RARP
This study is a retrospective, single-center clinical trial. It aims to retrospectively analyze the immediate postoperative urinary continence recovery in prostate cancer patients who underwent Retzius-sparing robot-assisted…
- Conditions
- Prostate Cancer (Post Prostatectomy), Urinary Continence, Retzius-sparing Robot-assisted Radical Prostatectomy
- Trial name
- NCT06850116
- Testing
- Retzius-sparing robot-assisted radical prostatectomy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
- Trial name
- NCT00588185
- Testing
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants…
- Trial name
- NCT00038168
- Testing
- Estramustine, Taxol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Stones, Prostate Cancer
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
Urological diseases such as urinary stones, prostate cancer, and bladder cancer are very common and often require highly specialized diagnosis and treatment.
- Conditions
- Urinary Stones, Prostate Cancer, Bladder Cancer
- Trial name
- NCT07721935
- Where
- 3 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses.
- Trial name
- NCT00363285
- Testing
- gonadotrophin releasing hormone, cyproterone acetate, quality-of-life assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 900 people
- Sponsor
- St. Bartholomew's Hospital
Prostate Cancer, Androgen Deprivation Therapy
Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer
The purpose of this study is to determine the rate of osteoporosis among patients with advanced prostate cancer. to propose an algorithm for early detection of patients with advanced prostate cancer who are at risk of developing…
- Conditions
- Prostate Cancer, Androgen Deprivation Therapy, Osteoporosis
- Trial name
- Osteoporosis (NCT00957606)
- Testing
- blood sampling, DXA-scan, bone scintigraphy
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Neoplasm, Prostate
Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer
Objectives I. Compare, in a randomized Phase III multi-institutional setting, symptom-free survival time of patients with asymptomatic carcinoma of the prostate (T0-4, N0-2, M0) not suited for local curative treatment who are…
- Trial name
- NCT01819285
- Testing
- Immediate Orchiectomy or depot LHRH, Delayed Orchiectomy or depot LHRH
- Volunteers
- 985 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostatic Neoplasms, Lymphatic Metastasis
Prospective Validation of Pathology-based Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in Prostate Cancer
The goal of this diagnostic test is to prospectively test the performance of pre-developed artificial intelligence (AI) diagnostic model for detecting pathological lymph node metastasis (LNM) of prostate cancer.
- Trial name
- NCT06253065
- Testing
- Artificial intelligence (AI)-based diagnostic model (developed)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Prostate Cancer
Olive Oil v Prostate Cancer Foundation Diet for Treatment of Prostate Cancer
This study compared a plant-based, olive oil diet to the diet recommended by the Prostate Cancer Foundation for weight loss and improvement in some laboratory biomarkers.
- Trial name
- NCT03084913
- Testing
- Plant- based, olive oil diet, Prostate Cancer Foundation diet
- Volunteers
- 30 people
- Sponsor
- The Miriam Hospital
Prostate Cancer
Imaging of Residual Tumor During Prostatectomy
Prostate Cancer is the most common cancer in men, affecting about as many men as women diagnosed with breast cancer, and killing about as many men per year as breast cancer kills women.
- Trial name
- NCT01173146
- Where
- United States
- Sponsor
- Spectros Corporation
Castration-resistant Prostate Cancer
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with…
- Trial name
- RAPIT (NCT04232761)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Taiwan
- Volunteers
- 194 people
- Sponsor
- Bayer
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Prostate Cancer
Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify genes related to cancer.
- Trial name
- NCT00959023
- Testing
- laboratory biomarker analysis, medical chart review, questionnaire administration
- Where
- 135 sites in United Kingdom
- Volunteers
- 21,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
The goal of this clinical research study is to find the highest safe dose of docetaxel in combination with Gleevec (imatinib mesylate) that can be given to men with advanced androgen-independent metastatic prostate cancer that…
- Trial name
- NCT00038194
- Testing
- imatinib mesylate, docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center